Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neuroblastoma 1Neoplasms 1Gulf War Illness 1Dermatomyositis 1Bites and Stings 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × Etanercept × Clear all
NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Amgen

Phase 1 Terminated
212 enrolled
Genitourinary

Bites and Stings, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡